BETA: Please send your feedback!
Xencor
XNCR:NAS
Biotechnology
$0
SMALL cap
$33.01
(-1.32%)
-0.09%
since start of 2020
52.12
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 1997
Xencor, Inc. is a clinical stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases, asthma & allergic diseases and cancer. Its clinical sate XmAb technology is used for the treatment of IgG4-related disease; systemic lupus erythematosus; asthma & allergic diseases; acute myeloid leukemia; B-cell malignancies; and neuroendocrine tumors. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| Bruce Leonard Andrews Carter, PhD | Chairman | Male |
| Bassil I. Dahiyat, PhD | President, Chief Executive Officer & Director | Male |
| John J. Kuch, CPA | Secretary & Vice President-Finance | Male |
| John R. Desjarlais, PhD | Chief Scientific Officer & Senior VP-Research | Male |
| Paul A. Foster, MD | Chief Medical Officer & Senior Vice President | Male |
| Stephen L. Mayo, PhD | Founder | Male |
| Mark W. Lotz | Vice President-Regulatory Affairs | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
Xencor - Competitors and Related Companies
How Xencor stacks up to its peers in the Biotechnology industry or with competing business segments.
Xencor
XNCR:NAS
Biotechnology
$0
SMALL cap
$33.01
(-1.32%)
-0.09%
since start of 2020
52.12
MacroGenics
MGNX:NAS
Biotechnology
$501.82mm
SMALL cap
$10.25
(-0.55%)
-0.10%
since start of 2020
-2.84
Alexion Pharmaceuticals
ALXN:NAS
Biotechnology
$23.30bn
LARGE cap
$105.30
(0.03%)
-0.02%
since start of 2020
16.03
AbbVie
ABBV:NYS
Pharmaceuticals: Major
$124.25bn
MEGA cap
$84.02
(0.48%)
-0.06%
since start of 2020
38.53
Amgen
AMGN:NAS
Biotechnology
$132.47bn
MEGA cap
$222.95
(-2.64%)
-0.08%
since start of 2020
17.00
Merck
MRK:NYS
Pharmaceuticals: Major
$219.21bn
MEGA cap
$86.10
(0.12%)
-0.06%
since start of 2020
23.85